Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases
in children. Recently, the management of JIA has substantially changed, thanks to the
availability of new treatment options, represented by biological drugs or biologics. These
drugs modulate the specific mechanisms of the immune systems, such as TNF-α, IL-1 and
IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a
comprehensive discussion on the current recommendations and clinical evidence regarding
the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic
and pharmacodynamic aspects of any specific biologic drug have been summarized.